Herceptin (trastuzamab) in advanced breast cancer

Cancer Treatment Reviews

Volumn 26, Issue 4, 2000, Pages 287-290

  Stebbing, J ^a   Copson, E ^a   O'Reilly, S ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b WATERFORD REGIONAL HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; DRUG RESPONSE; METASTASIS; REVIEW;

EID: 0034254775     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0182     Document Type: Review

References (26)

1. Lancet. 352:1998;930-942.
2. Chu K. C., Tarone R. E., Kessler L. G. Recent trends in US breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 88:1996;1571-1579.
3. Goldhirsch A., Glick J. H., Gelber, Senn H-J. International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Instit. 90:1998;1601-1608.
4. Rubens R. D., Bajetta E., Bonneterre J., Kljin J. G. M., Lonning P. E., Paridaens R. Treatment of relapse of breast cancer after adjuvant systemic therapy. Eur J Cancer. 30A:1994;106-111.
5. Coates A., Gebski V., Signori D. Prognostc value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol. 10:1994;1833-1838.
6. Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., Tinazzi A., Liberati A. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,510 women. J Clin Oncol. 16:1998;3439-3460.
7. Naboltz J-M., Senn H. J., Bezwoda W. R. Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 17:1999;1413-1424.
8. Daegardin M., Bonneterre J., Hecquw B. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol. 12:1994.
9. Stern D. F., Heffernan P. A., Weinberg R. A. p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol cell Biol. 6:1986;1729-1740.
10. Slamon D. J., Clark G. M., Wong S. G. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
11. Leitzel K., Teramoto Y., Konrad K. Elevated serum c-erb-B2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 13:1995;1129-1135.
12. Carlomagno C., Perrone F., Gallo C. c-erb-B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 14:1996;2702-2708.
13. Gusterson B. A., Belber R. D., Goldhirsch A. Prognostic importance of c-erb-B2 expression in breast cancer. J Clin Oncol. 10:1992;1049-1056.
14. Muss H. B., Thor A. D., Berry D. A. c-erb-B2 expression and response to adjuvant therapy in women with node-positive breast cancer. N Engl J Med. 330:1994;1260-1266.
15. Gianni L. Future directions of paclitaxel-based therapy of breast cancer. Semin Oncol. 24:1997;91-96.
16. Fehm T., Maimonis P., Teramoto Y. Influence of circulating c-erb-B2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat. 43:1997;87-95.
17. Di Fiore P. P., Pierce J. H., Kraus M. H. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 237:1987;178-182.
18. Guy C. T., Webster M. A., Schaller M. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA. 89:1992;10578-10582.
19. Lane H., Neve R., Daly J. D. Comparison of antibody mediated approaches for inhibiting ErbB2 overexpressing tumour cells (Abstract 22). 21st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1998.
20. Baselga J., Tripathy D., Mendelsohn J. Phase II study of weekly intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody in patients with HER-2/neu overexpressing metastatic breast cancer. J Clin Oncol. 14:1996;737-744.
21. Cobleigh M. A., Vogel C. L., Tripathy D. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 37:1999;2639-2648.
22. Vogel C. L., Cobleigh M. A., Tripathy D. Efficacy and safety of Herceptin as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer (HER2+/MBC) (abstract 23). 21st San Antonio Breast Cancer Symposium, San Antonio, TX, 1998.
23. Slamon D. J., Leyland Jones B., Shak S. Addition of Herceptin to first-line chemotherapy for HER-2 overexpressong metastatic breast cancer markedly increases anti-cancer activity: a randomised, multinational controlled phase III trial (abstract 377). Proc Am Soc Clin Oncol. 16:1998;377.
24. Norton, L. Slamon, D. Leyland-Jones, B. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2 overexpressing metastatic breast cancer. ASCO, Atlanta, GA, 1999.
25. Slamon D. J., Godolphin W., Jones L. A. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
26. Jacobs T. W., Gown A. M., Yaziji H. Comparison of fluorescence in situ hybridisation and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 17:1999;1974-1982.